The next-generation sequencing market valued at US$ 13.92 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, ...

The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 billion in 2024 and an impressive US$5.93 billion by ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target to $119.00. Discover outperforming stocks and invest ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...

In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck laid out their plans to overcome high-profile losses of exclusivity (LOEs) slated to dent sales through the end of the ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s coming loss of exclusivity can be managed. SAN FRANCISCO — For any hopes the dealmaking ...

Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "IVD Reagents Market by Type (Antibodies, Nucleic Acid Probes), Technology (Hematology), Application (Genetic Testing, Autoimmune Disease), Test Type ...

Summit Therapeutics (NASDAQ:SMMT), a drug developer challenging pharma giant Merck's (NYSE:MRK) dominance in lung cancer, won a new buy recommendation from Truist on Wednesday based on its deal ...

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...